Although patients with tumors harboring a PBRM1 mutation seem to have a shorter DFS versus patients with wild-type tumor (Fig. 1b), PBRM1 mutations did not appear to differentiate DFS outcomes in treatment-specific arms (Fig. 1e). The gene discussed is PBRM1; the disease is neoplasm.